Abstract
Integrating end-user perspectives into the design of new biomedical HIV prevention products is recognized as vital to informing the product development pipeline. Kisumu, Kenya; and Soshanguve, South Africa. We conducted a discrete choice experiment survey with 536 women aged 18-30 years to assess preferences for hypothetical HIV prevention products characterized by the attributes of efficacy, pregnancy prevention, delivery form, dosing frequency, and side effects. Participants included product-experienced women from Tablet, Ring, Injection as Options TRIO, a cross-over clinical study evaluating 3 placebo delivery forms (oral tablets, vaginal rings, and injections), and a product-naive sample recruited from the same communities. Analyses used random parameters logit and latent class models. HIV prevention efficacy was a strong determinant of stated choice overall; however, in South Africa, delivery form was just as important, with an injection every 2-3 months most preferred and a daily oral tablet least preferred. In Kenya, product-experienced women preferred monthly injections and least preferred a monthly ring. Respondents indicated a preference for multipurpose prevention technologies that combine HIV and pregnancy protection. Latent class analyses confirmed these findings and delineated heterogeneity in preferences across subgroups defined by age, past experience with the delivery forms, and education. Despite an overall preference for products with high efficacy, we identified attributes salient to future uptake and use of HIV prevention products. Preferences for injectable products underscored interest in this pre-exposure prophylaxis delivery form. Likewise, the multipurpose prevention technology feature was valued in both Kenya and South Africa and most influenced interest in vaginal rings.
Highlights
The HIV prevention field has increasingly recognized the importance of integrating end-user perspectives into the design of new biomedical HIV prevention products.[1,2] the ability to determine efficacy within large, randomized clinical trials and, achieve successful uptake of effective products depends on end users’ ability to initiate, persist with, and correctly use the product over time
Latent class analyses confirmed these findings and delineated heterogeneity in preferences across subgroups defined by age, past experience with the delivery forms, and education
We examined how the probability of selecting a particular form shifted when a multipurpose prevention technology (MPT) feature for pregnancy prevention was added to the HIV prevention indication
Summary
The HIV prevention field has increasingly recognized the importance of integrating end-user perspectives into the design of new biomedical HIV prevention products.[1,2] the ability to determine efficacy within large, randomized clinical trials and, achieve successful uptake of effective products depends on end users’ ability to initiate, persist with, and correctly use the product over time. Adolescent girls and young women in sub-Saharan Africa, a priority population at high risk of HIV, have been found to have lower adherence in studies of the vaginal ring and other delivery forms.[7,8,9] focusing end-user research on young women constitutes a priority to achieving and sustaining HIV prevention targets.[10] Discrete choice experiments (DCEs), a behavioral economics methodology increasingly used to measure patient preferences for medical treatment features,[11,12] engage respondents in considering a set of attributes that compose a potential product and in making choices that indicate the attributes and tradeoffs most salient to future uptake and use. Integrating end-user perspectives into the design of new biomedical HIV prevention products is recognized as vital to informing the product development pipeline.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
